オピオイド誘発性腸機能障害:グローバル臨床試験レビュー(2014年上半期)...市場調査レポートについてご紹介

【英文タイトル】Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Opioid Induced Bowel Dysfunction 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Opioid Induced Bowel Dysfunction to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Opioid Induced Bowel Dysfunction to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Opioid Induced Bowel Dysfunction Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Opioid Induced Bowel Dysfunction 28
May 21, 2012: Sucampo Presents Positive Phase III Trial Results Of Lubiprostone In Opioid-Induced Bowel Dysfunction At DDW 2012 28
Feb 06, 2012: Phynova Announces Preliminary Melokinex Phase II Clinical Trial Results 28
Feb 02, 2012: Sucampo’s Lubiprostone Meets Primary Endpoint in Phase III Clinical Trial for Opioid-Induced Bowel Dysfunction 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
GlaxoSmithKline plc 30
Clinical Trial Overview of GlaxoSmithKline plc 30
Cubist Pharmaceuticals, Inc. 31
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 31
Salix Pharmaceuticals Ltd. 32
Clinical Trial Overview of Salix Pharmaceuticals Ltd. 32
Sucampo Pharmaceuticals, Inc. 33
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 33
Shionogi & Co., Ltd. 34
Clinical Trial Overview of Shionogi & Co., Ltd. 34
Helsinn Holding S.A. 35
Clinical Trial Overview of Helsinn Holding S.A. 35
Clinical Trial Overview of Top Institutes / Government 36
Yokohama City University Hospital 36
Clinical Trial Overview of Yokohama City University Hospital 36
Mech-Sense 37
Clinical Trial Overview of Mech-Sense 37
Kuopio University Hospital 38
Clinical Trial Overview of Kuopio University Hospital 38
Five Key Clinical Profiles 39
Appendix 135
Abbreviations 135
Definitions 135
Research Methodology 136
Secondary Research 136
About GlobalData 137
Contact Us 137
Disclaimer 137
Source 138


【レポート販売概要】

■ タイトル:オピオイド誘発性腸機能障害:グローバル臨床試験レビュー(2014年上半期)
■ 英文:Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014
■ 発行日:2014年4月15日
■ 調査会社:GlobalData
■ 商品コード:GDHC2091CTIDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。